Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
CDx Diagnostics announces WATS3D data demonstrating crypt dysplasia as risk factor for esophageal cancer

CDx Diagnostics announces WATS3D data demonstrating crypt dysplasia as risk factor for esophageal cancer

CDx Diagnostics, an innovator in computer-synthesized, three dimensional tissue analysis for the early detection and surveillance of Barrett’s esophagus, today announced new data for WATS3D, or Wide Area Transepithelial Sampling with 3D Tissue Analysis, demonstrating the clinical significance of crypt dysplasia as an important risk factor for progression to high-grade esophageal dysplasia or esophageal cancer.

Dr. Nicholas Shaheen, Chief, Division of Gastroenterology & Hepatology University of North Carolina at Chapel Hill is presenting the data today in a Presidential Plenary session at ACG 2018, the annual meeting of the American College of Gastroenterology, taking place October 5 -10 in Philadelphia.

WATS Computer Synthesized En Face View of Crypt Dysplasia. Credit: CDx Diagnostics

Detecting still harmless, but pre-cancerous dysplasia can prevent the development of esophageal adenocarcinoma, the most rapidly growing cancer in the U.S., and one of the most fatal.

Accurately identifying which chronic heartburn patients who develop Barrett’s esophagus have also progressed to dysplasia can have an important impact on patient care.

The clinical significance of dysplasia involving crypt cells has not been well understood due to limitations in detecting crypt dysplasia by conventional biopsies. The data reported today suggest that samples obtained and analyzed with WATS3D allow detection of this condition.

Most importantly, the data also suggest that crypt dysplasia is something we should wish to detect, because it has a higher risk of progression to high-grade dysplasia or esophageal cancer compared to non-dysplastic Barrett’s. Together, the data suggest that WATS3D provides information that forceps biopsy cannot.”

Dr. Nicholas Shaheen

Barrett’s esophagus (BE) occurs when the normal epithelial lining of the esophagus is replaced by goblet cells that are typically found in the lower gastrointestinal tract.

Patients with BE have an increased risk of developing esophageal adenocarcinoma (EAC), a cancer that attacks 17,000 people in the United States each year – of which 16,000  will die from.

Given this risk, it is recommended that patients with BE undergo periodic surveillance endoscopy to monitor for pre-cancerous changes to the esophageal lining.

While non-dysplastic BE (NDBE), low- or high-grade dysplasia (LGD or HGD, respectively) can be diagnosed using standard biopsy criteria, morphologic changes that fell between NDBE and LGD were traditionally classified as indefinite for dysplasia and often grouped with NDBE due to the inability to distinguish dysplasia involving crypt cells (which are located below the epithelial cells) from esophagitis resulting from uncontrolled reflux.

Due in part to the inability to accurately diagnose crypt dysplasia (CD), its clinical significance has not been well understood.

The study results presented today are the first to show that WATS3D enables accurate diagnosis of CD as a distinct histology; they also show that CD is a risk factor for HGD and EAC and that progression rates from NDBE and LGD to HGD/EAC detected with WATS3D are similar to those obtained using traditional forceps biopsies.

What has been under appreciated by clinicians is how incredibly effective the WATS3D computer-assisted analysis and neural network program is at helping pathologists detect dysplasia and, most notably, its earliest form, termed crypt dysplasia.

The WATS 3D technology allows pathologists to ‘put into focus’ atypical lesions that would otherwise be considered indefinite.

The results of this study prove, for the first time, that early dysplastic lesions are clearly important to detect because of their now established increased risk of neoplastic progression. Thus, computer-assisted pathologic detection of these lesions will undoubtedly improve patient care.”

Dr. Robert D. Odze, Harvard Medical School

The study reported at ACG 2018 followed 4,512 patients who had two WATS3D assessments six months apart. Patient-years (pt-yrs) were calculated by multiplying the mean period of follow-up by the number of patients with each type of histology.

Of 4,512 patients, 4,049 with NDBE at baseline were followed for an average of 1.4 years between WATS3D assessments (5,736 pt-yrs) and 380 with NDBE at baseline were followed for an average of 1.25 years between assessments (475 pt-yrs). An additional 83 patients had LGD at baseline WATS3D and were followed for a mean of 1.25 years (103.7 pt-yrs). Key findings from the study include:

  • 19 of the NDBE patients followed for 1.4 years experienced progression to HGD/EAC, for a rate of 0.33%/pt-yr.
  • 10 of the NDBE patients followed for 1.25 years experienced progression to HGD/EAC, for a rate of 2.1%/pt-yr.
  • 8 of the LGD patients experienced progression to HGD/EAC, for a rate of 7.7%/pt-yr.
  • The overall rate of progression from WATS3D-determined CD to LGD/HGD/EAC was 9.9%/pt-yr, which is comparable to the rate of progression from biopsy-confirmed LGD.
  • Results show that a finding of NDBE or LGD on WATS3D predicts progression to HGD/EAC at rates that are comparable to or higher than the reported risk of progression when these histologies are determined by biopsy.
  • For patients with BE, CD or LGD at baseline, the trend for progression to HGD/EAC was statistically significant.

“These results highlight the clinical benefits that WATS3D provides with respect to accurate surveillance of esophageal changes in patients with BE,” said Mark Rutenberg, Founder and CEO of CDx Diagnostics.

“We believe these data highlight how WATS3D provides physicians and patients with accurate and critical information that can inform the management of BE and help preempt esophageal cancer. The fact that WATS3D accurately differentiates CD from reflux esophagitis, which is not feasible with forceps biopsy analyses, adds to its already compelling value proposition and advances our ability to achieve our vision of preventing unnecessary cancer deaths.”

Source:

https://www.cdxdiagnostics.com/

Tagged with:

About author

Related Articles